Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (237)	11/23/1998 6:05:00 PM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 1386

Another HU-211 potential competitor, SNX-111, drops out Elan announced that it was abandoning its Phase III trial of SNX-111 for head trauma. This was an advanced potential competitor to PARS' HU-211 that is no longer in the running. With potential competitor after potential competitor falling by the wayside, HU-211 is standing out as one of the only viable candidate drugs for the massive head trauma market. The Elan announcement also highlights just how impressive PARS Phase II results were. Many many companies have tried to find effective treatments for this indication and they have repeatedly met with failure. The HU-211 results, given this background, were just outstanding. Given the size of the market, the lack of competition, the desperate need for an effective treatment, and the HU-211 Phase II results, PARS should have no trouble not only finding a major Pharma partner, but should be able to negotiate very attractive terms. John de C